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Abstract  
Radiation therapy uses high energy radiation to kill cancer cells1. Radiation therapy for cancer 
treatment can take the form of photon therapy (using x-rays and gamma rays), or charged 
particle therapy including proton therapy and electron therapy. Within these categories, 
numerous methods of delivery have been developed. For example, a certain type of radiation 
can be administered by a machine outside of the body, called external-beam radiation therapy, 
or by a “seed” placed inside of the body near cancer cells, called internal radiation therapy or 
brachytherapy2. Approximately half of all cancer patients receive radiation therapy, and the 
form of radiation treatment depends on the type of tumor, location of the tumor, available 
resources, and characteristics of the individual receiving treatment3. In the current paper, we 
discuss and review the various forms of radiation therapy, the physics behind these treatments, 
the effectiveness of each treatment type compared with the others, the latest research on 
radiation therapy treatment, and future research directions. We found that proton therapy is 
the most promising and effective form of radiation therapy, with photon methods such as 
intensity modulated radiation therapy, 3D-conformal radiation therapy, image guided radiation 
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1.1 How does radiation therapy kill cancer cells? 
 The type of radiation that we are discussing in the context of radiation used for cancer 
treatment is called ionizing radiation. This is because it forms electrically charged particles in 
the cells of the tissues that it comes in contact with. It does this by removing electrons from the 
atoms and molecules in the tissues that it passes through4. This process kills cancer cells 
because it damages their DNA. The radiation can both damage the DNA directly by coming in 
contact with the cells or by creating free radicals (unstable molecules that can build up in cells 
and cause damage to DNA, lipids, and proteins) within the cells that then go on to damage the 
cancer cell DNA1,2. Ultimately, cancer cells with damaged DNA stop dividing and die. After 
death, these cells are broken down naturally in the body and eliminated2. As a result, the 
cancer has been combated and hopefully eliminated.  
 The overwhelming issue with this process is that radiation therapy does not exclusively 
attack cancer cells. It can just as effectively damage normal cells. This leads to serious side 
effects, which can be both acute (such as nausea and vomiting) and chronic (such as second 
cancers), damage to important organs, and other defects such as cardiac failure, endocrine 
deficiencies, or deafness. As a result, the amount of radiation that normal tissue can receive 
without significant damage is known for all parts of the body. For example, reproductive organs 
are more sensitive to radiation than bones2. Attention to sensitivity of nearby tissues, along 
with overall attention to reducing excess dose to healthy tissues, is central to treatment 
planning and decisions about which type of therapy is the best for a given case and how it 
should be administered2.  
      1.2 Treatment Process Overview 
 Creating a radiation therapy plan begins with a simulation. The tumor is imaged using 
one of four main types of scans: computed tomography (CT) scans, magnetic resonance imaging 
(MRI), positron emission tomography (PET), or ultrasound scans. A simulation is run using these 
images to plan the radiation therapy so that the target area is precisely located and well-
marked. Because the initial treatment and all subsequent treatment sessions are based off of 
the simulation, physicists and radiation oncologists go to great lengths to ensure that the 
patient is in the exact same position every day (relative to the machine administering the 
treatment). This includes the use and personalized construction of body molds, face masks, and 
skin markings to regulate patient positioning. After imaging and simulation the treatment plan 
is finalized and the treatment region, total radiation dose delivered to the tumor, dose 
allowance for neighboring healthy tissues, and safest angles and pathways to the tumor are 
determined and confirmed2. Again, central to the analysis of the tumor and the consideration 
of all of these factors is the decision of which type of therapy is best, and this decision relies on 
the physics of the particles and rays in question and the physics of the delivery tactics of the 
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machines. The exact treatment plan is developed using radiation therapy specific computer 
programs.  
 The radiation dose for cancer treatment is measured in grays (Gy). This is a measure of 
the amount of radiation energy absorbed by one kilogram of human tissue. The dose needed 
depends on the size, location, and specific type of cancer cell2.  
 Within each treatment plan, normal tissue surrounding the tumor is irradiated. Part of 
this exposure is simply due to the limitations in specificity of the technology or difficult tumor 
placement. However, a limited amount of radiation to nearby neighboring tissues is always 
calculated into the treatment plan to take into account body movement due to breathing and 
general organ movement, and also to reduce the likelihood of tumor regrowth due to cells that 
have spread to the normal tissue adjacent to the tumor site. The latter is called microscopic 
local spread. Essentially, the goal is to irradiate a small portion of neighboring tissue to ensure 
that the entirety of the tumor has been eliminated2.  
2. Types of Radiation Therapy  
 As stated previously, there are two main types of radiation therapy: photon therapy and 
charged particle therapy. Photon therapy is comprised mainly of gamma rays and x-rays while 
charged particle therapy usually takes the form of proton therapy and electron therapy. Within 
each of these branches, there are many ways to administer these therapies. The differences 
between the behaviors of each type of therapy are crucially important to recognize and 
understand. The type of radiation therapy prescribed depends on many factors including the 
size of the cancer, the type of cancer, the cancer’s location in the body, proximity to important 
organs and tissues sensitive to radiation, how deep in the body the tumor is, and patient 
considerations such as age, health, pregnancy, and medical history2. Much of the debate in 
radiation therapy is focused on proton therapy versus traditional photon therapy. However, the 
exact effectiveness of each type is heavily determined by the administration method in addition 
to the pure nature of each particle. The most important knowledge when deciding which type 
of radiation therapy to use is a deep understanding of the physics underlying each reaction, 
method of delivery, and tumor characteristic.  
 The focus of this review is on external-beam radiation therapy. Most forms of external-
beam radiation therapy are delivered using a linear accelerator. This machine uses electricity to 
form an extremely fast stream of subatomic particles. The linear accelerator uses microwave 
energy to accelerate electrons to speeds nearly the speed of light over a short distance. In the 
case of photon therapy, when the electrons reach maximum speed they collide with a tungsten 
target. This subsequently releases photon rays which are directed to the area of interest5. This 
creates high energy radiation that is given to patients daily for several weeks of treatment. The 
most effective linear accelerators can rotate to any angle around the patient so that the beam 
can be directed in the most favorable angles. Here, we dive into an in depth introduction to the 
most common forms of external-beam radiation therapy. 
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2.1 Photon Therapy – Overview 
 When a beam of x-rays or ϒ-rays passes through a medium, the radiation is delivered 
through energy transfer to the medium. This transfer begins with the ejection of electrons from 
atoms in the absorber, in this case the human body. These expelled electrons transfer their 
energy by creating ionization within the absorber and exciting atoms in their paths. The energy 
that results from this process deposits into the cells of the body and destroys their ability to 
reproduce15. This is different than in charged particle therapy, where the charged particles such 
as electrons and protons fall into the category of directly ionizing radiation where these 
particles have enough energy to produce radiation by collision. The radiation by uncharged 
particles, such as these photons, falls into the category of indirectly ionizing radiation because 
they act by releasing directly ionizing particles from the absorber material when they pass 
through it1,15.  
 The photon beam is characterized in a variety of ways. First, we consider the fluence, 
which we can understand as the robustness of the beam. The fluence (φ) of photons is the 
number of photons (dN) that enter an imaginary sphere of cross sectional area da given by 
(1)       
 
This can be adapted to represent the fluence rate or flux density (the fluence per unit time), the 
energy fluence (the sum of the energies of all of the photons that enter a sphere of cross-
sectional area da), and the energy fluence rate or intensity (the energy fluence per unit time)15.  
 Another important factor to consider is photon beam attenuation. By passing a beam of 
photons through an absorber of variable thickness and detecting the number of primary (non-
scattered and not-yet-interacting) photons at various depths, the beam attenuation was 
experimentally measured. It was found that the reduction in the number of primary photons 
(dN) is proportional to the number of incident photons (N) and the thickness of the absorber 
(dx). This is represented by 
(2)   
 
where μ is the attenuation coefficient. This coefficient depends on the energy of the photons 
and the nature of the material. There is a minus sign in the equation to show that the number 
of photons decreases as the absorber thickness increases. This can also be adjusted to be in 
terms of intensity where dI=-μIdx. When discussing the attenuation coefficient, the half-value 
layer is often mentioned. This is a sort of half-life equivalent term which is defined as the 
thickness of an absorber that is required to attenuate the beam intensity to half of its original 
value15. The attenuation of a photon beam is caused by four types of reactions: coherent 
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scattering, the photoelectric effect, the Compton effect, and pair production. Each of these 
have their own attenuation coefficient where  
(3)    μ=σcoherent + τ + σCompton + π 
and each of these components is the attenuation coefficient for the reactions listed above, 
respectively.  
 It is three of these processes - the photoelectric effect, the Compton effect, and pair 
production - that are the primary processes by which the ionizing photons interact with atoms 
in the absorber to produce the high speed electrons that create the therapeutic radiation. 
Coherent scattering, which was mentioned above, is left out of this discussion. That is because 
coherent scattering is an interaction with an electromagnetic wave passing near the electron 
and setting it into oscillation. This electron radiates energy in the same frequency as the 
incident electromagnetic wave, so the scattered x-rays have the same wavelength as the 
incident beam and no energy is changed and no energy is absorbed by the medium (figure 
1A)15. The other three processes, however, are crucial to an understanding of photon therapy.  
 The photoelectric effect is a process where a photon encounters an atom and ejects one 
of the orbital electrons from the atom. When this happens, the entire energy of the photon is 
absorbed by the atom and then transferred to the atomic electron. The ejection of this electron 
creates an empty space in the shell which leaves the atom in an excited state. The angle in 
which the electrons are ejected depends on the photon energy. For photons with lower 
energies, the photoelectron is emitted at an angle around 90 degrees relative to the direction 
of the incident photon. As the energy of the photon increases, the angle of photoelectron 
emission is directed in a more forward direction15. Because the incident photon is absorbed in 
the process and an electron is ejected, the photoelectric effect is both a reason for the 
attenuation of photons as the beam passes through material and an explanation for the 
therapeutic effects of photon radiation. This process is pictured in figure 1B.  
 The second process that characterizes photon radiation is the Compton effect. Here, the 
photon interacts with an atomic electron as though it were a free electron. This means that for 
this process to occur, the binding energy of the electron must be much less than the energy of 
the incident photon. The photon does not lose all of its energy and the electron receives some 
of the energy from the photon. The electron is emitted at an angle ϴ and the photon is 
scattered through an angle of φ (figure 1C). The process is thought of as a collision between 







where hv0 is the energy of the incident photon, hv’ is the energy of the scattered proton, and E 
is the energy of the electron. α=hv0/m0c2 where m0c2 is the rest energy of the electron15. 
Overall, the Compton effect occurs when the energy of the incident photon is much greater 
than the electron binding energy whereas the photoelectric effect is most probable when the 
energy of the photon is equal to (or slightly greater than) the binding energy of the electron.  
 The final process that produces high speed electrons and determines the attenuation of 
photons is pair production. If the energy of the photon is greater than 1.02 MeV, the photon is 
able to interact with the absorber material through pair production. Here, the photon gives up 
all of its energy when it interacts with the electromagnetic field of an atomic nucleus. This 
yields a negative electron and a positive electron. This is where the 1.02 MeV number comes 
from – the rest mass energy of the electron is 0.51 MeV so 1.02 MeV is required to create this 
pair. This process is an example of an interaction in which energy is converted into mass. 
Because the photon must interact with the electromagnetic field of the nucleus, the probability 
of pair production taking place increases with atomic number15. 
 While the energy of the incident photon dictates which sort of radiological process takes 
place, it also dictates the quality of the beam. Beam quality is the sharpness and homogeneity 
of the beam. Because high energy photons direct electrons in the forward direction after each 
type of collision, with increasing beam energy comes increasing beam quality and lateral 
conformity. There is less radial scattering with high energy beams.  
 To summarize the important features of this discussion and develop an overarching 
understanding of photon therapy, we must discuss the Bragg peak. This peak traces the path of 
the photon with respect to energy released and highlights what is called the entrance dose and 
exit dose, two very important features of photon therapy.  The orange curve, representing X-
ray delivery in human tissue, of the Bragg peak in figure 2B has a shape that is clearly 
significantly different in appearance than the respective proton curve (blue). The X-ray curve 
(which for these purposes, is representative of all forms of photon therapy) is characterized by 
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an entrance dose with a very high dose of radiation delivered to anterior tissues followed by an 
exponentially decreasing dose through the target tumor location and then an exit dose far 
more significant than that of the proton curve. When photons penetrate a material they 
consistently deliver radiation until the beam runs out of energy and the majority of photons 
have been eliminated through the attenuation reactions discussed. This results in the greatest 
amount of radiation being released at the surface and in shallow tissue (the entrance dose) and 
a significant amount of radiation penetrating past the target tumor and into healthy tissue 
behind the cancer (the exit dose). Instead of the depth dependent controlled dose that will be 
analyzed in our proton therapy discussion, we see a messy Bragg peak with radiation seeming 
to leak into a significant amount of healthy tissue. Entrance and exit doses to healthy tissues 
are not desired and can lead to a variety of negative side effects which will be discussed.  
 
 The Bragg peak, with photon therapy’s exit and entrance doses highlighted, is the first 
indication that photon therapy has some significant weaknesses. Over the years, however, a 
variety of creative and effective novel forms of photon dose delivery have been created. These 
address each of the issues inherent to photon therapy and make improvements. Each new 
technique builds off of the holes in the previous technique. The overall collection of photon 
therapy treatment methods has been able to side step some of photon therapy’s disadvantages 
in a more cost effective way12. The evolution of photon therapy strategies and each one’s 
strengths and weaknesses is presented below.  
2.11. Two-Dimensional Photon Therapy (Conventional Radiation Therapy) 
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 Conventional Radiation Therapy is the most basic form of photon therapy. Each of the 
following methods have addressed issues and oversimplifications in this treatment strategy and 
improved upon this design. 2D-PT uses X-ray films to determine how to position the radiation 
beams in order to target the tumor. A fluoroscopic simulator machine is used to plan the 
treatments where the bones on the X-ray image are used as landmarks to pinpoint the best way 
to position the radiation beams in order to eliminate the tumor. 2D therapy uses two 
unadjusted beams directed at the target from opposite sides11. In 2D treatment of breast 
cancer, for example, the breast is shaped such that the armpit and skin under the breast 
become “hot” during treatment where they receive a greater dose than the rest of the tissues 
that the photon beams pass through. This leads to skin burns2. While side effects like this with 
both short and long term implications are concerning, a potential benefit to conventional 
radiotherapy is that the treatment plan can be completed very quickly and patients are able to 
get their treatment as soon as necessary. For that reason, this technique is most commonly 
reserved for when urgent treatments are required11.  
2.12 3D Conformal Radiation Therapy (3D-CRT) 
 In 3D-CRT, the greater number of beams and greater variation in delivery angle allows 
the photon rays to be delivered from many different entry points, giving a lower dose to each 
section of tissue on the outer parts of the body and collecting each beam of radiation to deliver 
a strong dose to the tumor. Photon therapy is currently the most common form of radiation 
therapy. One of the most common types of photon therapy is 3D-CRT. This form of treatment 
uses sophisticated computer programming to create a 3-dimensional picture of the tumor2. 
First, a CT scan is conducted. This is translated to the treatment planning software that creates 
the 3D image of the tumor so that it is easier to determine the best beam direction and 
intensity for treatment. This allows for a more directed photon beam so that normal tissue can 
be spared. Because it uses several beams from different angles, 3D-CRT is able to improve upon 
the treatment delivered by 2D conventional photon therapy. The multi-angle optimized 
approach of the 3D-CRT allows side effects such as the skin burns and potential dangers in 2D 
conventional therapy to be avoided and leads to dose optimization in the tumor5. Of the most 
basic photon therapy techniques, 3D-CRT is favorable because it allows for treatment of tumors 
in sensitive areas such as the head and neck which are close to vital organs. It can safely treat 
these areas because of 3D-CRT’s spatial localization and ability to enter from precise angles.  
2.13 Intensity-Modulated Radiation Therapy (IMRT) 
 The key piece to IMRT treatment is the incredibly precise collimators integrated into the 
system. IMRT uses hundreds of tiny collimator pieces to shape the entry pathway for the 
photon beam. The machines administering this treatment have special collimator features built 
in that are able to individualize the collimator shape for each patient using layers of tiny nail 
shaped lead or tungsten pieces6. A special benefit to this setup is that the collimators can move 
during treatment, allowing for modulation of the intensity of radiation beams within a single 
session. With this, the result is a treatment plan that allows different areas of the tumor or of 
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nearby tissue to receive different doses of radiation. The collimators form many different 
shapes, typically 50 or more, during the course of a radiation treatment11. The strength of this 
feature and of the 3D features first introduced in 3D-CRT are illustrated in figure 3. Image 3A 
shows the treatment plan for 2D conventional radiation therapy for a patient with prostate 
cancer. A broad region is blocked out (yellow line) and multiple overlapping beams are used to 
create this brick shaped region of high dose delivery6. While this plan is fast and easy, an 
unwanted result is the irradiation of large volumes of the small bowel, rectum, and bladder. 
Image 3B shows a new treatment plan with the introduction of CT scanning and 3D-CRT. Here 
they were able to reconstruct the target volume three dimensionally and shape the radiation 
beams to fit the volume and begin to shield normal tissues. While they achieved improved 
spatial dose distribution, they were still unable to shield healthy surrounding tissues from 
exposure. Finally, image 3C displays an IMRT treatment plan. Here we see the most advanced 
plan that uses specific collimators to get an exact shape and takes advantage of non-uniform 
intensity of radiation beams. This is where the intensity modulation, one of the greatest 
novelties and strengths of IMRT, comes into play. In this image, strength of the dose in number 
of particles per second is represented by the color variation in the treatment plan image. The 
varied intensity is achieved by using many beams and subdividing each beam into hundreds of 
“beamlets” that each have an individual intensity level6. This means that multiple beams are 
arranged at various angles and then each of these beams is broken into hundreds of beamlets. 
All of this variation in this complicated dose delivery system comes together to create the 
incredibly complex treatment pattern in figure 3C.  
 An interesting aspect of the treatment planning for IMRT is that it is created in reverse. 
The oncologist and physicists select the radiation doses that they would like to deliver to each 
area of the tumor and adjacent tissue, feed this distribution into a computer program, and then 
this program calculates the required number of beams and the angle of delivery for the 
treatment plan7. This allows more effective treatment because the areas that need high dose 
are able to get increased radiation, while also allowing for a safer treatment process because 
sensitive healthy tissues are exposed to a significantly reduced dose. This delivery method 
improves upon some of the advances made between 3D-CRT and 2D radiation therapy by 
further reducing several common side effects and delivering a more localized beam and 
treatment plan. It is also particularly useful when the tumor has a concave or complex shape6. 
However, with IMRT, some studies alternatively suggest that a larger volume of normal tissue is 
exposed to radiation overall compared with 3D-CRT. IMRT also has the potential to be more 
risky than 3D-CRT. It is a complex treatment process that relies on extremely precise plots of 
direction, adjustment, and intensity of radiation beams. Because of this, great care must be 
taken to ensure absolute precision in patient placement because small movements on the 
millimeter scale as a result of breathing, heartbeat, or imprecise placement can distort the 
radiation pattern. Experimental comparisons between the two, as will be discussed, are critical 
to the development of an understanding of when each method is the superior choice given a 





2.14 Image Guided Radiation Therapy (IGRT) 
 In IGRT, throughout the course of treatment, imaging scans from either CT, MRI, or PET 
are repeatedly collected. Computer systems collect these scans and process them to identify 
real-time changes in tumor size and location due to the current treatment. This allows the 
position of the patient and the planned radiation dose to be safely adjusted during treatment. 
This results in increased accuracy in the treatment. It can also potentially result in decreased 
dose and planned volume of tissue to be irradiated – if the tumor has shrunk more than initially 
expected, they can cut down on the dose. This allows for an overall less harmful treatment2.  
2.15 Tomotherapy 
 Tomotherapy is one type of image-guided intensity modulated radiation therapy 
characterized by the use of a helical fan beam that delivers 360 degree radiation. This machine 
is a cross between a CT imaging scanner and an external beam radiation therapy machine. The 
machine collects CT images of the tumor right before each treatment session so that immediate 
adjustments can be made in response to patient weight fluctuations, tumor size changes, or 
other noticeable differences2.  
2.16 Volumetric Modulated Arc Therapy (VMAT) 
 In VMAT treatments, photon beams are delivered through a single modulated arc. This 
maintains accuracy while dramatically speeding up treatment time. Here, an algorithm for 
treatment plan optimization is employed where dose is delivered during a single gantry arc with 
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the potential to cover 360 degrees. This technique adopts some of the techniques from 
tomotherapy, such as the 360 degree rotation, but differentiates itself by delivering the entire 
dose volume in a single machine rotation of the source9. One other significant advantage over 
tomotherapy is that VMAT can do everything that tomotherapy can do, but can also be 
administered through normal LINACs configured to have VMAT capability. This is very cost 
effective and makes this treatment incredibly feasible10.  
 The use of VMAT has been steadily increasing since its onset. It was designed to make 
improvements from IMRT and IGRT in conformity of dose distributions, target volume 
coverage, sparing of normal tissues, and reduced treatment delivery time10. In recent years 
there has been an ongoing effort in the field to perform comparative studies between VMAT 
and the methods it was supposed to improve upon. This paper will compile some of these 
findings and analyze the body of results to determine whether VMAT is as effective as originally 
expected.  
2.17 Stereotactic Radiosurgery (SRS) 
 SRS is characterized by its extremely accurate image-guided dose delivery. Because of 
this, it is able to give relatively high doses to a small tumor. The benefit of this method is high 
dose delivery without increased damage to normal tissues. This method, however, is limited to 
small tumors with clear edges and regular shapes. It is usually employed for brain or spinal 
tumors. In this form of photon treatment extreme head or other body part stabilization is 
crucial to a safely administered treatment8. Because of the high dose, the physicists and 
oncologists must be certain that they are hitting the tumor and thus the tumor region must be 
clearly defined.  
2.18 Stereotactic Body Radiation Therapy (SBRT) 
 SBRT is the adaptation of SRS that treats tumors outside of the brain and spinal cord. 
This photon treatment type is characterized by fewer treatment sessions, smaller radiation 
fields, and higher doses than 3D-CRT and other conventional techniques. This technique is more 
susceptible to body movements and cannot be directed as precisely as SRS tumors and is 
therefore limited to small, isolated tumors8. Both SBRT and SRS use fiducial markers either on 
or within the patient to ensure that the dose is going to the exact location of the tumor because 
precision is so important in these methods14. 
2.2 Proton Therapy 
 While photon therapy has greatly improved since its onset with the development of 
more effective and safe techniques, photon therapy is still marred by the way that it deposits 
its energy in tissues with great entrance and exit doses. We are left wanting a better radiation 
therapy solution that does not litter healthy tissue with radiation on the way to the tumor. The 
fundamental advantage to using protons instead of photons for radiation therapy lies in the 
way that they deposit energy in living tissues. While photons deposit energy in small packets all 
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throughout their path to their intended target location, protons, on the other hand, deposit the 
majority of their energy at the end of their path. This allows proton therapy to reduce the 
radiation dose delivered to normal tissue in treatment and makes it possible to deliver higher 
doses to the target tumor. In addition to depositing energy in a more ideal location, protons are 
also higher energy than the options in photon therapy so they are more effective as well.  
 In addition to releasing their energy at a certain depth without significant release during 
travel, protons are also useful because the depth at which they release their energy can be 
precisely controlled11. The proton also releases very little energy beyond this desired depth. 
This allows protons to be used to treat tumors that are located against vital organs or the spinal 
cord, for example. To show this visually, we turn back to the Bragg peak in figure 2. Image 2B 
visually summarizes the clear benefits of proton therapy. These trace the path of the proton 
with respect to energy released and highlight the burst of energy released when they reach the 
site of the tumor. In proton therapy, the Bragg peak is an important tool and results in proton 
dose delivery that can be placed at any depth in the tissue. The radiation therapy physicists 
manipulate this depth by controlling the velocity of the proton13. What is important to reiterate 
in figure 2 is the differences in shape of the peaks between protons and photons. The proton 
peak is characterized by a low dose of radiation until the energy burst at the top of the peak 
and then an extremely sharp drop-off after the expulsion of radiation. This is a clear visual 
representation of the concept that there is limited radiation exposure to tissue as the proton 
travels through the body, a large dose of radiation delivered at the peak where the tumor is 
located, and then a sharp drop-off after dose delivery so that radiation is not delivered to 
healthy tissue beyond the tumor. In conclusion, the main goal in radiation therapy is to 
eliminate the tumor while also minimizing the damage to healthy tissue. Protons behave in 
such a way that the achievement of this goal is maximized. This discussion will provide a more 
detailed explanation of the physics that lead to the characteristics of this peak.  
 There are three primary types of interactions of protons in matter. These include 
Coulombic interactions with atomic electrons, Coulombic interactions with the atomic nucleus, 
and nuclear reactions. Along the course of travel, protons continuously lose kinetic energy 
through Coulombic interactions with atomic electrons. The rest mass of a proton, however, is 
1,832 times greater than that of an electron, so therefore most protons typically travel in a 
straight line (figure 4A). This is therapeutically advantageous because it allows for more control 
over the path of the proton. In some trajectories, a proton passes close to the atomic nucleus 
and experiences a repulsive elastic Coulombic interaction. Because the nucleus has a large 
mass, this deflects the proton off of its straight line course of travel (figure 4B). Finally, it is also 
possible to have non-elastic nuclear reactions between traveling protons and the atomic 
nucleus. These interactions are far less frequent but can have much more profound effects. 
Here, the proton enters the nucleus and in response the nucleus may emit a proton, deuteron, 
triton, or neutron (figure 4C). Neutron emission is particularly dangerous during treatment and 
requires close attention during our comparative analysis12. In terms of therapeutic 
consideration, each of these interactions determines one dimensional component of the 
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treatment beam. The first interaction, inelastic Coulomb scattering pictured in figure 4A, leads 
to continuous energy loss that determines the depth range of beam travel in the patient. The 
second interaction, elastic Coulomb scattering in figure 4B, results in a change in trajectory and 
therefore determines the lateral penumbral sharpness of the beam. The third interaction, non-
elastic nuclear reactions results in the removal of primary protons from the beam and therefore 
affects the fluence of the beam12.  
  
 As previously mentioned, the control of protons in proton therapy relies on the energy 
loss rate of ions, called linear stopping power. This is defined as the quotient of dE and dx 
where E is the mean energy loss and x is the distance. However, it is believed to be more 
convenient to express the energy loss rate such that it is independent of the mass density. The 
mass stopping power is defined for a beam (not a particle) as  
(7)  
 
where ρ is the mass density of the absorbing material. The energy loss rate can also be 
described based off of the Bragg-Kleeman rule where the energy loss rate is  
(8)  
 
where ρ is the mass density of the material, α is a material-dependent constant, E is the energy 
of the proton beam, and p is a constant that is included to take into account the proton beam 
energy’s dependence on velocity12. Because the first form of interactions of protons in matter 
(figure 4A) is most common, it is most physically meaningful to state that the linear stopping 
power is proportional to the density of electrons in the absorber. Essentially, components such 
as the velocity of the proton and the absorber material can strongly influence the energy loss 
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rate. The material density in the human body can vary by about three orders of magnitude from 
air in the lung to cortical bone12. Therefore, when a treatment is plan is created, the specific 
path in the body that the proton will take is a critical piece of the plan.  
 Another important consideration when seeking to understand the behavior of protons 
in radiation therapy is range. In this case, range is defined as the depth in which half of the 
protons in the medium have come to rest12. There are small fluctuations in the energy loss of 
individual protons, which is called range straggling, so as a result range is an average quantity. 
The range is therefore defined for a beam and not for individual particles. Overall, however, the 
proton path length is effectively a straight line with a path length nearly equal to its projected 




where E is the ion’s initial kinetic energy and the summation represents the calculation of 
continuous transport approximated by calculations in discrete steps12. 
 The range can also be calculated by using an analytical approach. This depends on the 
knowledge that the proton range of interest can be as deep as 30 cm (the midline of a large 
male’s pelvis which is considered to be the deepest point in the human body) and as near as 
1mm.  This range corresponds to 11 MeV and 220 MeV12. The correlation between the 
logarithm of range and logarithm of energy has been found to be linear which means that the 
range of the proton may be calculated following a simple power law. This is the Bragg-
Kleemann rule for range where 
(10)   
 
and again α is the material dependent constant, E is the initial energy of the proton beam, and 
p accounts for the dependence of the proton’s energy or velocity.  
 The next important consideration is lateral scattering from elastic Coulomb scattering 
due to interactions with the nucleus. Even a small change in proton trajectory is important and 
must be taken into account when designing beamlines and calculating dose distributions in 
patients. To characterize the amount that the beam is misshaped by scattering, physicists 





where <ϴ2> is the mean squared scattering angle and x is the thickness of the absorber (so for 
therapeutic purposes, human tissue). In addition to this, the mass scattering power is T/ρ 
where ρ is the mass density of the absorber material. When developing predictions of elastic 
Coulomb scattering, the number of scattering events Ns that occur in a given absorber is used. 
For multiple Coulomb scattering, the combined effect of all Ns events can be statistically 
modeled. This statistical approach can predict the probability for a proton to scatter by a net 
angle of deflection. The most complete theory for clinical proton therapy is the Moliere theory 
which focuses on the net effect that many small angle scattering events have on the collection 
of protons. This translates to an understanding of lateral spatial distribution of dose in a 
patient. Using the small angle approximation, Moliere theory is described by 
(12)  
 
where η=ϴ/(ϴ1B1/2), ϴ1=0.3965(zZ/ρβ)root(ρδx/A) and d(Ω) is the solid angle that the particles 
are scattered through. Z is the atomic number, A is the atomic mass, δx is the thickness, ρ is the 
mass density, z is the proton charge, β=ν/c, and B can be found by solving g(B)=lnB-B+lnϒ-
0.154=0. In this equation for B, ϒ=8831qz2 ρδx/(β2AΔ), and Δ=1.13+3.76(Zz/137β)2. Finally, the 
Fk(η) functions are defined as 
(13) 
 
and Jo(ηϒ) is a Bessel function. This is a very complicated theory and simpler versions and 
alternatives do exist. However, the simpler alternatives are not nearly as accurate and the 
Moliere theory is the most respected and relied on13.  
 In some aspects of proton theory, this multiple Coulomb scattering is useful because it 
allows intentional beam spread and thickening so that the tumor can be completely covered 
with a uniform dose. However, uncontrolled multiple Coulomb scattering in the treatment head 
and within the patient blurs the lateral sharpness of the treatment13. In order to use proton 
therapy to its maximum potential and harness the method into a truly effective tool, we must 
understand how to preserve this lateral penumbral sharpness to a very precise degree.  
 The final “dimension” affecting control of proton therapy that must be considered is 
beam fluence changes due to nuclear interactions. This results in a decrease in absorbed dose 
due to the removal of primary protons. This is partially replenished by secondary protons that 
result from these interactions and deliver dose. However, the other side of the emission of 
secondary protons is minor decreases in beam conformity. Another more hazardous result of 
non-elastic nuclear interactions is the production of free neutrons. These are extremely 
penetrating and have relative biologic effectiveness up to 20 times higher than that of proton 
radiation13. These free neutrons can lead to a variety of health issues which will be discussed 
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further. Efforts to minimize this byproduct of proton therapy have been employed and are 
crucial to the safe delivery of proton therapy.  
2.3 Electron Therapy 
 Electron therapy is the second main form of charged particle radiation therapy. Because 
of their lower energy level, electron beams cannot travel far through the body. The most 
clinically useful energy range for electrons is 6 to 20 MeV15. Electron therapy treatment, 
however, is very effective. For this reason it is widely used to treat superficial tumors such as 
skin cancers on or near the surface of the body11. At this energy range, electron beams can 
treat tumors less than 5 cm deep15.  While this limits the variety of uses for electron radiation, it 
is also an advantage because the electrons are able to treat superficial cancers without 
penetrating too deep into the body and harming healthy tissues11. The electron therapy beam is 
characterized by a sharp drop-off (similar to that of proton beams) in dose beyond the tumor15. 
While this is part of its range limitation, it also allows for safe delivery because the dose is 
highly controlled with depth and it spares healthy tissues. Overall, there are five main 
categories of therapies that are good fits with electron therapy: treatment of skin and lip 
cancers, chest wall irradiation for breast cancer, administering boost dose to nodes, and 
treatment of head and neck cancers15. The processes of energy loss, interactions with atoms, 
and dose delivery are very similar between electrons and protons. Electrons interact with 
atoms in the absorber in the same way that protons do and the stopping power is determined 
by the sum of collisional losses and radiation losses. One difference is that electrons are far 
more susceptible to scattering with a scatter pattern that can be modeled by a Gaussian 
distribution. This leads to issues with dose delivery sharpness and must be taken into account. 
Overall, the main difference between electron and proton radiation is the scale, with electrons 
being much smaller than protons and the same size as the electrons that they interact with, but 
this simply results in the limited depth that differentiates electron therapy from proton 
therapy. 
3. Comparative Review of the Most Commonly Used and Most Effective Treatment Methods 
 For the comparison in the current paper, the focus is on the particle and photon 
treatment modes that are most often used or most highly researched and show significant 
therapeutic potential. This includes intensity modulated radiation therapy, 3D conventional 
radiation therapy, volumetric modulated arc therapy, image guided radiation therapy, 2D 
conventional radiation therapy, and various types or proton therapy, among other forms. We 
analyzed the body of research discussing each type of radiation therapy technique and its 
strengths and weakness and developed what we believe to be the five categories of 
consideration that are of the greatest importance when conducting a comparative analysis of 
these treatment modalities and planning a cancer treatment. These include precision and 
specificity of delivery, dose delivered to healthy tissue and associated risks, risk of second 
cancer, time that the treatment takes, and feasibility of treatment.  
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3.1 Precision and Specificity of Delivery 
 When discussing the effectiveness of each form of radiation therapy, the first step is a 
brief analysis of relative abilities to achieve maximum dose delivery precision for each method 
of radiation delivery and each form of radiation. From here we can dive deeper and tackle other 
implications of dose control and analyze the overall performance of each method of delivery. 
Several innovations have led to drastically improved precision in beam conformation and 
delivery. The most notable are the advancements in imaging and the onset of image guided 
therapy, the use of intensity modulated therapies that control the exact dose delivered to each 
region of the target area, and the development of tools that can account for limited specificity 
within certain delivery methods. When we discuss precision in radiotherapy we are referring to 
the precise delivery of radiation to targeted areas by combined utilization of radiotherapy, 
computing, and physics16. This is characterized by four qualities: the delivery of very high 
radiation doses to targeted tumors, limited exposure of normal tissue to radiation, precise dose 
homogeneity and conformity and attention to treatment plan quality, and precise localization 
of the tumor area. In our comparative research through the literature, we found that proton 
radiation therapy was on the high end of the precision scale and that several photon therapy 
methods including IMRT, SRS, IGRT, and VMAT rivaled this precision.  
 Proton therapy is inherently precise because of the large size of protons and their ability 
to penetrate human tissue, whereas electron therapy is characterized by scattering and 
concerns about particle control. Once minor beam variation due to the small angle redirection 
of protons through repulsive Coulomb elastic scattering is accounted for, proton beams are 
able to precisely deliver their dose to the desired range. Even with this slight lateral scattering, 
the lateral scatter in proton therapy is significantly less than the amount of lateral scatter in 
photon therapy25. Many studies have verified that proton therapy delivers a more uniform and 
precise dose than respective photon therapies. We specifically studied several papers that 
reported significant improvements in control of craniospinal irradiation with proton therapy. 
These included the studies by Lee et al., Miralbell et al., Slater et al., and St Clair et al. While 
each of these studies had relatively small sample sizes, the results were consistent across each 
study and supported the precision of proton therapy over photon therapy18,19,20,21. The more 
recent paper by Howell et al. conducted a similar study to these and compared therapeutic 
dose distributions for photon and proton craniospinal irradiation for a group of 18 patients. The 
patients underwent CT simulation and then treatment plans for proton and conventional 
photon therapy were created and analyzed. They found that proton craniospinal irradiation 
provided more homogeneous target coverage and conformation to the target region than 
photon therapy for patients across a wide age and BMI spectrum22. This indicates an overall 
greater level of treatment control and precision in proton therapy.  
 The only major concern within proton therapy is the production of secondary particles 
such as free neutrons. The path of these particles is not directed or controlled and they can 
lead to health concerns. There are three distinct sources of radiation exposure during 
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treatment, all illustrated in figure 5. The beneficial and purposeful radiation is the therapeutic 
protons pictured in red. The second is stray neutrons from the treatment apparatus pictured in 
blue. The third, also pictured in blue and marked by horizontal arrows, is neutrons produced by 
therapeutic proton radiation inside of the body. When the proton beam is created, a small-
diameter beam of protons enters the treatment apparatus. The apparatus spreads the beam to 
a clinically useful size and collimates it to the desired target size that will irradiate the tumor 
and spare healthy tissue. Within the treatment apparatus, proton induced nuclear reactions can 
take place, which yields stray neutrons which can leak out and irradiate the patient. Again, 
these reactions can also take place within the patient. These neutrons provide no therapeutic 















 Some have said that while proton therapy is incredibly promising, its use is not justified 
because of incomplete research on the dangers of stray neutron exposure27. This is a partial 
hole in understanding in the field that more research should be dedicated to. Proton therapy is 
one of the hardest therapy forms to simulate, so these studies are a bit more difficult than 
similar studies in photon therapy. While this is an important area to dedicate more research, 
some promising studies have been published recently. In one study, it was found that the risk 
or radiogenic side effects from stray radiation is small but not negligible. However, the risk 
posed from using photon therapy rather than proton therapy is even greater12. Taddei et al. 
found that by adding shields near the patient, using a tungsten-alloy collimator, and adding an 
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upstream collimator after the range shifter assembly, they were able to reduce the neutron 
dose by 66% in prostate cancer patients28. Currently, there are several good Monte Carlo 
simulations that model stray neutron dose. Future research in this area should focus their 
efforts on developing stray dose algorithms that are possible to implement into treatment 
planning programs and used for clinical purposes. Brenner et al. did some preliminary research 
on ways to limit stray neutron dose and found that various pre-collimator and collimator 
combinations with different geometries, distances, and materials paired with various proton 
energies greatly affected the stray dose. These factors could be combined to form an optimized 
design for each treatment case to significantly reduce stray neutron dose29. This optimization 
may be a good starting point for algorithm development and future research.  
 For photon therapy, IMRT is at the top of the discussion about precision because not 
only does it utilize extremely specific multi-leaf collimators that allow for precision in the shape 
of the beam relative to the tumor, but it also delivers a different dose to each region of the 
tumor and controls the dose to deliver a low but deliberate dose to healthy tissue neighboring 
the cancer region. Within each beam there are beamlets of different intensity levels that allow 
for a huge degree of freedom to create a precise treatment plan. Various studies such as Teoh 
et al.10 and Chang et al.24 have experimentally determined that IMRT has significantly greater 
dose control than other more primitive photon therapies. Chang et al. studied 25 patients with 
medically inoperable Stage I or Stage III non-small-cell lung cancer (NSCLC). They compared the 
3D-CRT, IMRT, and proton radiotherapy. They found that proton radiotherapy had the overall 
best performance and delivered the most controlled dose, but that IMRT was able to achieve a 
much greater dose escalation than 3D-CRT without losing control of radiation placement24.  
 The paper by Teoh et al. discussed advantages in VMAT precision in terms of its ability 
to allow for the simultaneous variation of three parameters during treatment. These included 
gantry rotation speed, treatment aperture shape with the use of multi-leaf collimators, and 
dose rate. Where IMRT requires the use of many superimposed arcs to achieve their dose 
distribution, VMAT can treat the entire target volume using one or two arcs. Essentially, it is a 
form of single arc intensity modulated therapy that can also use dose rate variation10. In the 
study by Cozzi et al., they conducted a planning study comparing VMAT with IMRT in eight 
patients with cervical cancer. The results showed similar target volume coverage between the 
two, but VMAT demonstrated improved dose homogeneity and conformity17.  
 The studies discussed above indicate that VMAT can do more and has the ability to 
improve its precision rating based on a greater number of variables that can be adjusted to 
perfectly fulfill a treatment plan. However, when we compare quality assurance between VMAT 
and IMRT, looking at the raw ability of the two methods to accurately carry out a treatment 
plan without too much rogue dose delivery and variation, they preformed similarly. The study 
by Mancuso et al. constructed treatment plans for both VMAT and IMRT. The plans were 
repeatedly delivered across multiple measurement sessions and the resulting dose distributions 
were measured using both radiochromic film and ionization chamber and a commercial two-
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dimensional diode array. The QA measurements from each delivery technique were analyzed, 
compared, and run through a statistical analysis. They found that of the 22 comparisons IMRT 
showed better QA results in 11 cases and VMAT showed better QA results in 11 cases. So, 
although differences between the two plans were noted, neither mode of dose delivery showed 
consistently better precision26.  
 Image guided radiation therapy benefits from the implementation of imaging 
throughout the treatment session so that the precision of photon therapy can be maximized 
through a greater understanding of the location and shape of the tumor throughout treatment. 
IGRT is most often used in conjunction with IMRT to create a very precise proton therapy 
treatment plan2. However, a major hole in the body of radiation therapy research is the need to 
develop an understanding of the best way to guide radiotherapy with the images produced, 
either for target volume definition or prognosis stratification16. Future studies on IGRT should 
seek to translate precise target delineation into better tumor control and integrate it more 
deeply into the treatment process so that the two processes (imaging and treatment) are not 
two separate steps but rather one imaging process that dictates the implementation of the 
other.  
 In certain cases, it is not feasible to use the most precise methods of radiation therapy 
delivery. In these cases, adjustments must be made to provide safe and controlled therapy with 
conventional treatment methods. For example, as discussed above, 2D-CRT has many 
significant disadvantages (such as skin burns, lack of dose control, and the development of hot 
spots in the patient), but is still used when immediate radiation therapy is required because of 
the method’s allowance for the rapid development of treatment plans and fast administration. 
An important development is the use of individually shaped bolus to minimize dosimetric 
heterogeneities. This means that they are reducing hot spots in thinner regions of anatomy and 
cold spots in thicker regions22. This forces dose conformity and homogeneity. Bolus is a material 
which has properties equivalent to tissue when irradiated. When placed on the surface of a 
human receiving therapy, bolus can be used to alter dosing. It is most often used in cases of 
irregular tissue shape which result from normal (or abnormal) variations in the shape of the 
human body. Bolus can be polythene bags that take the shape of the skin surface, certain waxes 
sculpted to fit the specific shape needed by the radiation physicist, or Perspex which is acrylic 
glass. It can both serve as a missing tissue compensator to level the tissue or as a way to 
increase the dose to the patient’s external surface (mostly for electron therapy)23. Several 
groups are doing research on bolus therapy and improving bolus effectiveness. This is an 
important direction in the field so that precision can be maximized no matter which method of 
delivery is available.   
3.2 Dose Delivered to Healthy Tissues 
 Directly related to precision of delivery method is the dose delivered to healthy tissues. 
This is the next step in the analysis after beam control and precision and includes a variety of 
negative side effects. When broadly comparing proton therapy to photon therapy with dose 
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delivered to healthy tissue in mind, we must return to figure 2 with the Bragg peak representing 
the dose delivery pattern of these two forms of radiation therapy. Again, a very clear model of 
the increased dose delivered to healthy tissue in photon therapy is the entrance dose and exit 
dose regions in the Bragg curve. Proton therapy is inherently structured so that the dose is not 
delivered until the proton beam reaches its desired depth. Photon radiation is expelled with 
enough energy to deliver a significant dose to the desired depth, but results in significant 
irradiation of the tissues on the way into the body and past the tumor. With photon therapy the 
idea of depth is less concrete and does not represent the area of dose delivery but rather a stop 
along the path of exponentially decreasing tissue irradiation from the skin to the point when 
the beam runs out of energy. This is the underlying feature driving the following comparisons 
investigating the dose of radiation delivered to normal tissues.  
 Zhang and colleagues compared proton and photon therapies in terms of predicted risk 
of second cancer for a 4 year old medulloblastoma patient receiving craniospinal radiation. 
They compared a passive scatter proton therapy beam line with intensity modulated photon 
therapy. Their results show an example of the realization of the implications in the Bragg curve 
of figure 2. Figure 6 shows the absorbed dose distributions for this 4 year old boy’s treatment. 
Figure 6A shows the photon therapeutic absorbed dose distribution and 6B shows the proton 
therapeutic absorbed dose distribution. In the photon dose image, the dose fall off is much 
more gradual than that of the proton image. This is highlighting the effect magnitude of the exit 
dose marked in figure 2. The proton dose stays in the craniospinal region, but the photon plan 
spreads radiation to all of the critically important organs in the surrounding area. Finally, image 
6C is the stray neutron dose distribution from proton therapy. While the dose is far lower in 
magnitude than the therapeutic proton dose, this image does a good job of highlighting how 
widely stray neutrons are able to penetrate the body and invade healthy tissues31.  
 This paper is limited by the single-patient sample size. The nature of the comparison, 
between two verified best-option treatment plans, allowed for this sample size to be relatively 
reasonable. However, it would be important to make similar comparisons in future studies 





















 The study by Howell et al. is similar to the work by Zhang and colleagues, but compared 
conventional photon therapy to proton therapy for craniospinal irradiations (CSI) for 
medulloblastoma. They developed photon and proton treatment plans for 18 patients, 
including both males and females with various ages and builds. They found that proton CSI 
spared normal tissues significantly better than photon CSI. Figure 7 shows the dose 
distributions for photon and proton treatment plans for a representative patient. In these 
images the 100% dose line (red) indicates the intended treatment region. From the figures we 
can see that the prescribed dose covers all of the vertebral bodies in the proton plan but only 
covers the spinal canal in the photon plan. We can also see that the proton dose quickly 
decreases after the 100% dose line and the photon plan delivers significant dose far outside of 
this region. As a result of this, we also notice that tissues and organs near the target volume are 
exposed to significantly lower doses in the proton plan than in the photon plan. This is also 
represented in the dose volume histogram of figure 8 where we can clearly compare the dose 
that each important organ receives between photon treatment and proton treatment. In 
essentially every organ the radiation exposure differences are very clearly significant to the 
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naked eye. Across the board photon therapy exposes healthy organs to a greater dose (figure 
8). Quantitatively, they found that on average the photon plans were 8% hotter than the proton 
plans. The dose to healthy organs was especially bad in the organs that were located anterior to 






 Another study, by Chang and colleagues, tackled the comparison of dose to normal 
tissue between 3D-CRT, IMRT, and proton therapy for 25 patients with Stage I or Stage III lung 
cancer.  First, they found that proton radiotherapy reduced the normal tissue dose in Stage I 
and Stage III lung cancer compared with 3D-CRT. In this treatment comparison they found that 
proton therapy spared the contralateral lung, heart, spinal cord, and esophagus. It also reduced 
the low-dose exposure in the ipsilateral lung. The mean total lung dose was 9.7 Gy for photon 
therapy with a prescribed dose of 66 Gy whereas the dose was 5.4 Gy for proton therapy with a 
prescribed dose of 66 CGE. This resulted in an absolute improvement of 19%. The total body 
mean non-target dose was reduced from 5.3 Gy at 66 Gy photon therapy to 2.1 Gy at 66 CGE 
proton therapy which is a 61% absolute improvement. The rest of the organ results can be 
visualized in the dose value histogram in figure 9. It is clear to the naked eye that proton 
therapy greatly improves upon photon therapy. The results were similar for comparisons 




 For the comparison between IMRT and proton therapy, they found that proton therapy 
reduced the dose to normal tissue compared with IMRT. Here doses to the lung, heart, spinal 
cord, and esophagus were again reduced. For the patients treated with IMRT, the mean lung 
dose was 20.1 Gy for photon therapy at the prescribed 60 Gy dose and 17.5 Gy for proton 
therapy at that dose. The body mean non-target dose was 6.8 Gy at a prescribed 63 Gy dose for 
photon therapy and 4.5 Gy at 63 Gy with proton therapy. This was a 34% improvement. We see 
here that even with the improvements that IMRT makes upon 3D-CRT, the advantage is still 
clearly in favor of proton therapy. This is pictured, for the rest of the organs as well, in the DVH 





 Overall they found that in each case, proton treatment significantly reduced the dose to 
the lungs, esophagus, spinal cord, and heart. Additionally, the non-target integral dose had a 
33-61% absolute improvement with proton therapy. Notably, in stage I disease, proton therapy 
treatment almost completely spared the contralateral lung, heart, esophagus, and spinal cord. 
Finally, it is important to consider that with lung cancer treatment, respiratory motion adds a 
great level of complexity and danger to treatment. We recall that IMRT is able to reduce normal 
tissue toxicity in many cases, but its high dose gradient and conformity require a very high level 
of precision in dose delivery and therefore tumor localization. Therefore, a moving tumor 
makes IMRT less effective. This allows the proton therapy to demonstrate even greater 
strength because each proton beam typically treats all target volume, not just a portion like 
IMRT does. This results in proton treatment being more effective for a moving target24.  
 It has been demonstrated that VMAT delivers a comparable or decreased dose to 
healthy tissues and organs at risk than IMRT10. One earlier study, by Cozzi et al., found that 
VMAT reduced the dose to healthy tissues by 12% compared with IMRT17. Rotational arc 
therapy distributes a lower dose over a larger volume of normal tissue than static beam 
radiotherapy30. Because of these differences, it is important to study the dose distribution in 
arc therapy. In the recent study by Rechner and colleagues, they compared the dose 
distributions between VMAT and proton arc therapy. They found that the VMAT and proton arc 
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therapy treatment plans sufficiently covered the target, where at least 99% of the planning 
target volume (PTV) received at least 76 Gy of dose. Figure 11 shows that proton arc therapy 
delivered a lower dose over a smaller volume of normal tissue than VMAT. This is clearly 
illustrated in figure 11 where the dose VMAT in image 11A seems to flood the body. It is 
noteworthy that the high dose is certainly restricted to the PTV, but the significance lies in the 
comparison between the two methods where proton arc therapy is clearly more controlled and 
does a far greater job of keeping the dose from irradiating healthy tissues. Numerically, they 
found that on average, proton arc therapy reduced the volume of normal tissue receiving doses 

















 Finally, it is important to touch upon the variety of health concerns that significant 
radiation dose exposure to healthy tissues can cause before diving into one of the most 
significant negative effects, the development of second cancers. Merchant and colleagues 
conducted a study in pediatric brain tumors to compare photon and proton therapy dose 
characteristics and their relationship to cognitive function. They used models that have been 
developed to correlate radiation dose to normal tissue volumes with functional outcomes. They 
have found links between normal tissue irradiation and abnormalities in growth and 
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development and endocrine and cognitive function. Using a sample size of 40 cases, they 
studied four types of childhood brain tumors, optic pathway glioma (OPG), craniopharyngioma 
(CR), infratentorial ependymoma (EP), and standard risk medulloblastoma (MB), and found that 
proton beam therapy was able to improve outcomes for children with brain tumors because of 
its ability to reduce dose to normal tissues. The dose volume histograms in figure 12 show the 
difference in the volume of normal tissue exposure to radiation between photon therapy (red) 
and proton therapy (blue) in the hypothalamus, left temporal lobe, left cochlea, and total brain.  
 
 They then compared model-estimated spelling scores on the Wechsler Intelligence Test 
(WIAT) from normal tissue brain dosimetry values for both forms of radiation. This led to the 
determination of the estimated IQ score as a result of radiation. They found that in OPG, MB, 
and CR, there was a significant difference in IQ outcomes between proton and photon therapy 
with proton therapy preserving cognitive function more effectively. They were not able to make 
a comparison for patients with EP. Figure 13 shows a representative IQ plot showing the 
difference in estimated WIAT score for patients with OPG planned for treatment with proton 
therapy (blue) and photon therapy (red). As time after treatment increases, the differences in 















 They also considered the effects of radiation therapy on growth hormone deficiency. 
The dose to the hypothalamic-pituitary axis predicts endocrinopathy in patients. They found 
that in patients with EP, proton therapy can avoid growth hormone deficiency, based on 
location and size of the tumor. For patients with MB, the strength of the dose of radiation to 
the tumor determines whether or not there will be negative endocrine side effects. It is easier 
to spare tissues from high dose radiation with proton therapy than photon therapy and this 
modality was therefore found to reduce central hypothyroidism, gonadotropin insufficiency, 
and adrenal insufficiency. Finally, they considered hearing loss, which can be a result of brain 
tumor irradiation. They found that in all cases across all tumor types, the protons provided dose 
distributions that were significantly below the threshold for radiation induced hearing loss25.  
3.3 Risk of the Development of Second Cancers 
 When discussing the variety of serious side effects that can occur when normal tissue 
gets too great a dose during radiation therapy, one of the most serious is the development of 
second cancers, which falls into the category of “negative late effects” because of its late onset 
(on the scale of years) after cancer treatment. After smoking, the development of second 
cancer as a result of normal tissue exposure to radiation is the second most studied 
carcinogen3. While the individual risk of developing a second cancer after radiation therapy is 
often quite low, there are, for example, on the order of 3,000 new cases of cancer caused by 
radiotherapy in the prostate alone each year30. This means that any reduction in risk of the 
development of second cancer could have a very significant impact on public health across the 
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board. In this section we will also discuss studies that demonstrate how the dose delivered to 
healthy tissue can result in the development of second cancers. 
 IMRT plans use a larger number of monitor units (MU) compared with conventional 
plans and proton therapy. This leads to an increase in the amount of low dose radiation to 
healthy tissues. This increase has led to concerns of increased risk of secondary radiation-
induced malignancies. VMAT achieves many of the benefits of IMRT while significantly reducing 
the use of MU10. While IMRT has many great advantages, preventing second cancer may not be 
one of them. In fact, one early study suggested that the incidence of second cancers may nearly 
double with IMRT compared with conventional radiation therapy (from 1% to 1.75% for 
patients surviving 10 years)27. Because of these initial findings in the early research, we thought 
a comparison between IMRT, VMAT, proton therapy, and conventional radiotherapy as it 
relates to secondary malignancies in recent research was critical to this discussion.  
 First, one study by Fontenot and colleagues assessed the risk of second cancers from 
proton therapy relative to IMRT. They considered both primary and secondary sources of 
cancer and focused their research on prostate cancer. They created treatment plans and ran 
their results through risk models from the Committee on the Biological Effects of Ionizing 
Radiation. They found that proton therapy reduced the risk of secondary cancer by 26-39% 
compared with IMRT. Even in organs directly in field of the treatment path, proton therapy 
greatly reduced the risk of second cancers compared with photon therapy.  
 Next, the study by Brodin and colleagues compared the risk of second cancers in 
pediatric patients with MB treated with 3D-CRT, inversely optimized arc therapy, or intensity 
modulated proton therapy. They found that estimates of second cancer risk were highest for 
arc therapy treatment. However, they also found that the risk of developing heart failure, 
hearing loss, hypothyroidism, and xerostomia was highest for 3D-CRT. The risk of all adverse 
effects was lowest for proton therapy plans. This is with the inclusion of secondary neutron 
dose. Photon therapy does not lead to secondary neutron radiation, but this study and others 
demonstrate that even with that photon therapy advantage, proton therapy is still far safer 
when it comes to adverse effects.  They estimated that the risk of second cancers in this type of 
cancer was 45%, 56%, and 7% for 3D-CRT, arc therapy, and proton therapy for 23.4Gy 
prescribed dose, respectively. For 36 Gy prescribed dose, the risk of second cancer 
development over the patient lifetime was 54%, 71%, and 9% for 3D-CRT, arc therapy, and 
proton therapy, respectively. In figure 14A we see the dose distributions from the three 
treatment types noting that, again, proton therapy has the smallest dose range with limited 
dose spreading to healthy tissues. Figure 14B shows a plot of the absolute risk of the 
development of second cancers after each of these treatments. The volume of normal tissue 




 The results from studies like the ones previously discussed have demonstrated that 
proton therapy reduces the predicted risk of second cancer when compared to intensity 
modulated radiation therapy and other forms of photon therapy such as 3D-CRT. In response to 
this knowledge, Rechner and colleagues studied whether this advantage persists when proton 
arc therapy is compared with volumetric modulated arc photon therapy. They compared the 
predicted risk of cancer following both of these treatment types for three prostate cancer 
patients. They analyzed the dosimetric data using five risk models and found the excess relative 
risk (ERR) of cancer in the bladder and rectum and calculated the ratios of these ERR values 
between proton arc therapy and VMAT. They even expanded their results to make direct 
comparisons with those from the Fontenot study discussed above32.  
 Because rotational arc therapy distributes a lower dose over a larger volume of normal 
tissue than static beam radiotherapy, it cannot be assumed that the predicted risks of second 
cancer incidence in VMAT are comparable to those from IMRT and other static beam 
radiotherapy techniques. This was a primary motivation for Rechner and colleagues’ choice of 
VMAT as a treatment type to study. The other motivation was the effectiveness and safety of 
proton arc therapy. Overall, they found that proton arc therapy significantly reduces the 
predicted risk of radiogenic second cancer in the bladder and rectum compared with VMAT. 
This was only true, however, in four of the five risk models. The linear-non-threshold risk model 
found no significant difference between the two. This slight discrepancy further highlights the 
need for many reliable risk models and the development of improved risk models. Overall, 
however, the results indicate that there is a difference between the two treatment techniques. 
The absolute individual risk of developing a second cancer from treatment was translated from 
their models to be about 1-2%. The best summary of the results from this study is in table 1 
below where they compared their arc therapy ERR data with the ERR data from the Fontenot et 
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al. 2009 study comparing IMT with parallel-opposed beam proton therapy. ERR is the rate of 
cancer in exposed population relative to the rate of cancer in an unexposed population minus 
1. They found that the risk of second cancer from therapeutic radiation following VMAT was 
less than that following IMRT and that the risk following parallel-opposed beam proton therapy 
was less than the risk following proton arc therapy (table 1).  
 
 Interestingly enough, proton arc therapy has not yet been clinically implemented, but 
has been proposed. This paper suggests that proton arc therapy’s implementation would be 
beneficial in terms of dose to healthy tissues and risk of second cancer. Future studies should 
look to investigate other aspects of proton arc therapy such as feasibility, cost of 
implementation, regularity, and other aspects of safety. The implementation of this technique 
seems promising and particularly intriguing to us. For that reason we included a discussion of it 
in the current review and suggest that this would be a valuable and exciting direction of focus 
for future research30.   
 It is interesting to note that the body of research studying the risk of developing second 
cancers after radiation therapy treatment is based on predictions through risk models. It seems 
obvious to suggest that the field would benefit from a longitudinal study tracking actual 
individuals who have undergone each form of radiation therapy and recording the incidence of 
second cancers. This, however, would not work. The reason highlights the fascinating pace of 
the field of radiation therapy physics. A longitudinal study is useless because innovations in 
dose delivery are created so quickly that the clinical lifetime of a technique is far shorter than 
any longitudinal study. This makes it incredibly difficult to form a complete understanding of 
the risk of developing a second cancer. The field would benefit from increased attention to the 
development of more risk prediction models so that each body of results can be compared with 
several different models in order to shape a clearer picture of the probabilities.  
3.4 Treatment Time 
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 Treatment time also plays a role in the selection of therapy method. If a certain method 
takes too long, this may result in a treatment that raises the individual survival rate while 
sacrificing the population survival rate when fewer individuals can be treated. As a result, 
treatment time is an important consideration. We do not need to devote a detailed discussion 
to this topic, but a brief overview is important.  
 The use of VMRT over IMRT in recent years has grown due to its decreased dose to 
organs at risk and reduced treatment time30. The typical VMAT treatment period lasts 1-1.5 
minutes where the typical IMRT treatment lasts 5-10 minutes10. In addition to this, the planning 
and quality assurance processes required for IMRT are more complicated, and as a result, time 
consuming compared with both VMRT and IMRT10. Image guided radiation therapy relies on 
time for imaging before and during the treatment process. This is one of the main drawbacks 
for IGRT – more time on the treatment couch and as a result, increased radiation delivered to 
the patient10. Because of its fast delivery time and low dose of radiation due to fewer monitor 
units, VMRT could maximize its potential through the incorporation of image guided 
radiotherapy. Where other modalities that take longer are made less useful by the 
incorporation of imaging, VMRT is fast enough that it could reasonable incorporate this extra 
dimension of treatment capacity. It is important to reiterate that when time is of the utmost 
importance and immediate delivery is required, the fastest treatment type is 2D-CRT, which is 
often used in these emergency cases11. Proton therapy is generally known to fall into the 
middle of the pack in terms of treatment time, and the proposed proton arc therapy, as 
discussed in the review of the Rechner paper, is expected to reduce treatment times even 
further12.  
 3.5 Feasibility 
 The one result that is overwhelmingly persistent throughout the body of comparisons 
previously discussed is the strength of proton therapy. Until this point, it seems simple that the 
future lies in the proton therapy realm and appears as though it is silly to even consider photon 
therapy. All of this research and the body of promising proton results comes crashing down 
when feasibility is discussed.  
 Currently, there are only 25 cancer centers conducting proton therapy treatment in the 
United States. There are only 12 other centers that have proton therapy programs under 
construction. This means that in the near future, in order to receive proton therapy, one would 
most likely have to travel quite far and stay in hotels near a center for a prolonged period of 
time. This would mean missing work, being away from home, and an overall great deal of hassle 
and sacrifice. These clinics also have long wait lists so even if someone was open to this level of 
commitment, he or she may not be able to be treated. 
 The reason that there are so few proton therapy centers is that this treatment form is a 
great deal more expensive than any photon therapy treatment form. As of 2012, proton 
therapy required an investment of $100 million to $180 million34,35. The MD Anderson Cancer 
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Center reported that when patients of various insurance and payment plans are all considered, 
proton therapy delivery costs an average of $37,000 per patient for prostate treatment 
whereas IMRT costs $29,000 per patient and standard radiation treatment costs $21,000 per 
patient34. The cost differential in 2012 actually reflects a significant improvement over the last 
decade. In 2003, it was estimated that proton therapy was 2.4 times more expensive than 
photon therapy36. Proton therapy also requires the construction of an entire buildings to house 
the machines. They are extremely large and require three stories of building space and then 
additional treatment-associated areas11. This means that even if a cancer center has enough 
money to take on proton therapy, they may not have the space to do so. And of course, even if 
they have the space, the construction of a proton therapy building would require an investment 
of time and significant additional funds.  
 One of the most important advancements that can happen in the field of medical 
physics is the development of novel ways to bring down the costs of proton therapy. In this 
review we have come to the conclusion that proton therapy is often the best choice of 
treatment modalities. It is also, sometimes, the only choice. Photon therapy is incredibly 
ineffective in eye cancers. Currently, the most commonly employed option is complete eye 
removal. Studies, however, have shown that proton therapy can safely combat eye cancers. 
Studies as early as 1999 in France have demonstrated that proton therapy can fight cancer 
while also saving the eye and in a reported one third of cases, restore vision to useful levels34. 
This in itself seems to justify the need for increased feasibility of proton therapy.  
 The 2015 study by Newhauser and colleagues sought to investigate ways that the 
expenses associated with proton therapy can be minimized. They approached this by looking at 
collimators, range compensators, and hypofractionation. They suggested several cost-reducing 
modifications and tested their clinical strength compared with the typical proton therapy 
instruments. First, they replaced custom proton therapy fabricated collimators with a multileaf 
collimator. Next, they examined the impact of eliminating custom range compensators. They 
assessed these effects in 10 patients. They also assessed the risk of the development of second 
cancers after these modifications and examined the potential for hypofractionation, which is 
radiation therapy given in large doses over a shorter period of time than standard radiation 
therapy. They found that their adjustments had a negligible effect on the predicted dose 
distributions and the risk of developing a second cancer. Overall, their results showed that we 
are able to find ways to reduce treatment costs without sacrificing treatment quality37.  
4. Conclusion 
 The comparison in this review suggests that proton therapy is the best available 
treatment option for the majority of cases of cancer requiring radiation therapy. In each 
comparison outside of feasibility, including strength and effectiveness of treatment, dose 
delivered to healthy tissues, risk of negative side effects, and treatment time, proton therapy 
was found to be the best option. When feasibility is considered, however, proton therapy 
automatically drops to the least effective treatment because no matter how good it is, if people 
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cannot be treated by this method, it becomes useless. This means that we are essentially left 
with problems entirely within the control of the resources that we allocate to cancer treatment. 
With improved cost effectiveness or greater financial allocations to cancer treatment, and 
possibly the development of reduced machine size, we are on the brink of greatly improving 
cancer treatment. This, in combination with rapidly increasing innovations within the 
framework of available therapies, gives us great hope that we can continue to improve cancer 
care. 
 An interesting consequence of this body of research is that if proton therapy is not 
available, medical physicists are left with a complicated choice. We have seen that some forms 
arc therapy and IMRT lead to significantly higher chances of second cancer. On the other hand, 
3D-CRT is likely to result in a variety of other very serious side effects such as heart failure and 
hearing loss. This highlights a very large hole in the body of medical physics research and an 
important future direction of study that results from all of the comparisons discussed in this 
paper. It is clear that if proton therapy is not available, there is a multitude of conflicting and 
confusing data in the photon therapy realm. One may be far superior at treating the cancer at 
hand while leading to the development of unwanted second cancers. Another may lead to a 
lower risk of second cancers but have a high risk of leading to heart failure and hearing loss. 
One form may be far faster than the others so that a greater proportion of the population can 
be treated, increasing population survival while potentially decreasing individual survival rates.  
As a result, there is a strong call for mathematical modeling of risk comparisons that can guide 
clinical decision making. If there is one takeaway from this analysis other than the strength of 
proton therapy, it is that the choice of treatment modality for a given cancer is a very 
complicated process. It is also a process where we would like to make absolutely sure that we 
have made the correct decision. The development of a mathematical model that can assess the 
clinical robustness and effectiveness of a treatment type for a given tumor type, size, and 
location while also taking into account the various secondary risks associated with treatment 
would be an absolutely critical advancement.  
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